Almost against the odds, Sarepta’s gene therapy for muscle-wasting disease Duchenne muscular dystrophy (DMD) has been given accelerated approval by the FDA, albeit in a fa
Adults aged 60 and over in the US will be eligible for vaccinations with respiratory syncytial virus (RSV) vaccines from GSK or Pfizer later this year, if the Centers for
Legal challenges to Medicare’s price negotiation initiative introduced in the Inflation Reduction Act (IRA) continue to emerge, with pharmaceutical trade organisation PhRM
Pfizer has won FDA approval for its PARP inhibitor Talzenna in castration-resistant prostate cancer (CRPC) in a combination that it hopes will help it challenge AstraZenec
The market for drugs to treat the muscle-wasting disease generalised myasthenia gravis (gMG) is getting more crowded, and Argenx has just claimed an FDA approval that coul
Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th Oc
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.